Emissions and impacts of waste at disposal sites cemnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cemnet.com Daily Mail and Mail on Sunday newspapers.
FRIDAY, Oct. 21, 2022 (HealthDay News) Surgery can be a daunting prospect at any age. Now, researchers say they ve spotted two key factors upping the odds of a poor
Santiago de Cuba, Dec 23 (Prensa Latina) Four decades of a journey to the roots through traditional popular culture will be held until next June by the Casa del Caribe, announced authorities of the entity that today is preparing for renovation.
Share this article
Share this article
HOUSTON, March 4, 2021 /PRNewswire/ DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced the treatment of the first patient in a Phase 1 dose-escalation and dose-expansion study of DNX-2440, an OX40 ligand encoding oncolytic adenovirus, in patients with resectable liver metastasis. Expression of OX40 ligand on the surface of tumor cells is expected to enhance anti-tumor immune responses by providing costimulatory signals to T cells within the tumor microenvironment. We are excited to clinically explore the potential of one of our immunotherapy drug candidates, which is based on our proprietary adenovirus platform technology, in additional cancer indications, said Jeffrey Knapp, chief executive officer of DNAtrix. Our preclinical work with DNX-2440 has demonstrated that infection of human tumor cell lines with this agent leads to viral replication, high level expression of OX40 ligand on tumor cell